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Summary 
We consider the problem of deciding optimally whether a-characteristic 
exists based on one or two screening tests. We discuss the relative merits of 
giving either one or two tests, including the order in which they might be 
given, as well as their costs. Operating in the Bayesian mode, we utilize 
posterior distributions for the accuracies of the tests, and the prevalence of 
the characteristic. Applications to detecting rare conditions, such as the AIDS 
virus, are discussed. 
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1. Introduction 
With the introduction of multiple diagnostic tests for various conditions, 
including pre-clinical diseases, and the need that the public health of a 
population be carefully monitored so that appropriate informed actions can be 
taken when necessary, mass screening programs have been suggested. It is the 
purpose of this paper to set forth the requisite decision theoretic framework 
for such programs involving the estimation of the critical entities such as the 
prevalence, sensitivity, specificity, various predictive probabilities all 
combined with the costs of the tests and the utilities (or losses) for taking 
particular actions. 
We assume a relevant population and a diagnostic test to ascertain the 
presence of a characteristic in a randomly drawn unit from the population. In 
the medical area, diagnostic tests are often used to attempt to confirm or 
indicate the preclinical or presymptomatic presence or near future onset of a 
disease. We first confine ourselves to a simple binary diagnostic test and 
develop the necessary tools for the full analysis of this situation. Then we 
consider two binary diagnostic tests given simultaneously or in sequence. Here 
the framework for the estimation of the attributes of the tests and their 
optimal administration for a mass screening program is considered. Costs of the 
tests and the losses associated with the various kinds of correct and incorrect 
diagnoses are also taken into account. In all that follows we assume that a 
diagnostic test is always capable of assigning every individual of a particular 
population as a positive or negative for the characteristic, even though this 
may not always be the case with real diagnostic tests. In particular the so-
called gold standard test, that is the Western Blot test, for the presence of 
HIV antibodies can apparently result in four categories namely positive, 
probably positive, indeterminate and negative (Lundberg, 1988). Furthermore, 
ELISA tests often give equivocal results. We interpret equivocal results as 
positive. 
Comparisons of two or more screening tests are made routinely in the medical 
and veterinary literature, for example see Burkhardt, Mertens, and Eggers, 
(1987); Sandstrom and Mortimer, (1987); Ghi et al., (1988); Hirsch, Searcy, and 
Bellamy, (1982); Jarrett, Golder, and Weijer, (1982); and Kurlander, Hill and 
Enterline, (1955). Most of these articles compare single tests with one 
another; Kurlander et al. (1955) consider combined tests. Data obtained in such 
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studies are generally not "ideal". An absolute gold standard often does not 
exist; while in other instances, not all individuals are subjected to the gold -
standard when it exists. Future 1experiments should obtain full information 
regarding the joint accuracies of multiple tests by confirming not only 
questionable test results, but also those results that are apparently, though 
not necessarily, unequivocal. G~stwirth (1987) discussed the problem of making 
inferences from screening data and gave many references to previous work. 
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Geisser (1987) discussed the Bayesian approach with special emphasis on 
I prediction problems. Gastwirth and Hammick (1989) considered pooling blood so 
that anonymity could be maintained while estimating prevalence. Johnson and 
Gastwirth (1988) and Gastwirth, Johnson and Reneau (1988) developed Bayesian 
methodology for making approximate statistical inferences about prevalence, 
sensitivity, specificity, etc. based on screening data. Gatsonis and Iyengar 
(1987) developed Bayesian methodology for screening data based on the 
approximations developed by Tierney and Kadane (1986). 
We detail the setting for a single diagnostic test in section 2, and for two 
diagnostic tests in section 3. In section 4, we incorporate the possibility of 
differential costs for the various possible administrations of the two tests. 
We illustrate our procedures in section 5, and make some final remarks in 
section 6. 
2. A Single Diagnostic Test 
In order to introduce ideas we first consider a single diagnostic test. 
Define the following relevant quantities: 
ff - Pr(C) 
the probability that a randomly drawn individual from the population exhibiting 
characteristic C, 
~ - Pr(TIC) 
the probability that the test correctly diagnoses the absence of C, which is 
called the sensitivity, 
9 - Pr(TIC) 
the probability that the test correctly diagnoses the absence of C, which is 
called the specificity, 
~ - Pr(CIT) - ff~/{ff~ + {l-ff){l-9)} 
the probability that the characteristic is present given the test indicates its 
presence, which is called the prkdictive value positive {PVP), and 
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Pr(CIT) - (1-ff)8/(ff(l-q) + (1-ff)D} 
the probability that the characteristic is absent given the test indicates its 
absence, which is called the predictive value negative (PVN). When all of these 
entities are known, conceptually we need only introduce the costs, or utilities, 
and a few manipulations to determine an optimal decision procedure given an 
outcome on the diagnostic test. 
Precise knowledge of ff, q and 8 is often unavailable, or only partially so, 
in terms of samples from various subpopulations within the relevant population. 
Normally 8 and q will be unknown and their estimation would require independent 
random samples from two reference populations; the test is applied ton 
individuals or units known to have the characteristic, and also ton individuals 
known to be free of the characteristic. Assuming that rout of n yield Tin the 
first sample and rout of n yield Tin the second, we obtain the likelihood 
-
L(q,8) « qr(l-q)n-r8r(l-8)n-r. 
If ff is unknown, and an independent sample of size v from the entire population 
is available, we have the additional likelihood contribution 
t v-t 
L(ff) « ff c(l-ff) c (2.1) 
where t represents the number of individuals having C. If this is unavailable, 
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another independent sample of sizes from the population could be obtained. In 
this sample we ascertain the number t that test T. Since 
Pr(T) - wq + (l-ff)(l-8), we obtain the joint likelihood 
- - -r n-r r n-r t s-t L(q,8,ff) « q (1-q) 8 (1-8) (ffq + (l-ff)(l-8)} (ff(l-~) + (1-ff)8} . 
Alternatively, a random sample of size.n+n from the population of interest could 
be obtained and each individual given the screening test as well as a "gold 
standard" confirmatory test. In this case, one finds that the likelihood is in 
exactly the same form as L(q,O)L(ff), thus we do not discuss it further. 
Given a prior density, p(q,8,ff), and with d - (r,n,r,n,t ,v), the joint 
C 
posterior density is obtained as 
p(~,8,ffld) « p(q,8,ff)L(8,q)L(ff). 
With d - (r,n,r,n,t,s), 
p(q,8,ffld) « p(~,8,ff)L(8,~,ff). 
In both cases, the main quantities of interest are the predictive probabilities 
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Pr(C I(+), d) 
Pr (CI ( - ) , d) 
E(~l(+),d) E(ff~ld)/(E(ff~ld) + E((l-ff)(l-8)ld)}, 
E(~((-),d) - E(8(~·ff)ld)/(E(8(1-ff)jd) + E(ff(l-~)jd)}, 
I 
(2.2) 
(2.3) .. 
both obtained by simple application of Bayes Theorem. Gastwirth, Johnson and 
Reneau (1988) and Johnson and Gastwirth (1988) gave results in this setting 
where the prevalence was low and the accuracies were high. 
Clearly, the predictive probability is the same for all exchangeable 
subjects. Hence, when a positive result is obtained, a decision regarding 
various alternative actions depends on the particular subject's costs, or 
losses. Assume that there are "a" actions and that for action i, the generic 
losses are liC and liC' the loss associated with taking action i when C is true 
and of taking action i when C is true, respectively; i=l,2, ... ,a. Then we need 
only minimize 
with respect to i, to obtain the optimal action. The predictive probability of 
C is the same for any individual that tests positive, but individuals may very 
well differ in the utilities they would assign. If expenses for each action, 
say ci' are in the same units as the losses, then we would minimize 
E(Lil(+)) + ci. A similar analysis could hold for those that tested negative. 
Another point of considerable importance is the potential variation in the 
prevalence of the characteristic amongst subpopulations at any given time. For 
example, with AIDS it is well known that there are substantial increases over 
the general population in the prevalence of the Human Immunodeficiency Virus 
among intravenous drug users, homosexuals, and hemophiliacs. In other 
situations there are population characteristics, which are neither lethal nor 
contagious, for which the prevalence may be more or less stable over time. 
However with highly contagious diseases this is obviously not so. Depending on 
the ease of transmission, time varying prevalence could be of critical 
importance if the screening is to be made over a protracted time period. We 
shall restrict ourselves here to situations where ff is considered to be largely 
stable. 
We defer discussion of choice of prior and actual calculations to the end of 
the next section. Results for single tests can be obtained as special cases of 
results in section 3. 
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3. Two Tests 
In this section, we allow for the availability of two distinct tests that 
may be administered either simultaneously or sequentially in a screening 
program. There are a number of different decision rules one can follow 
regarding how to proceed. If one were to administer two tests simultaneously, 
one could assert that the characteristic exists or pre-exists if both tests are 
positive or if either test is positive. A decision could be made to ignore one 
of the test results and to simply designate C or C according to a single test's 
result. One could administer the tests sequentially and allow for the 
possibility of administering one test first and then either stopping if the 
result were positive, or proceeding to a second test if the result were 
negative. The final decision would be to designate as C either a positive on 
the first test or a negative on the first and a positive on the second. Another 
sequential possibility is to give a single test and to designate C if the result 
is negative, otherwise give the second test and designate Conly if both tests 
are positive. 
We denote our single test results as (T.,T.) i=l,2 and introduce notation to 
1 1 
indicate the above decision rules. There are eight possibilities that we will 
discuss. They are listed in Table 1. 
Rule 
1 
2 
3 
4 
5 
6 
7 
8 
Table 1 
Decision Rule (Assert C if} 
Test 1 is positive 
Test 2 is positive 
Both tests positive (simultaneous tests) 
Either test positive (simultaneous tests) 
Both tests positive (sequential tests) 
Both tests positive (sequential tests) 
Either test positive (sequential tests) 
Either test positive (sequential tests) 
Notation 
Tl 
T2 
(T1T2) 
(TlUT2) 
TlT2 
T2Tl 
Tlvi'1T2 
T2UT2Tl 
Decision rule, #8 say, resulted in a positive result, hereafter denoted(+), if 
test #2 was administered first and was positive or if it was negative and then 
test #l was subsequently positive. The eight omitted possibilities correspond 
to invalid tests; for example, assert C if Test 1 is negative. 
There are expenses associated with the tests, and losses in making wrong 
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decisions. Ye defer discussion of expenses until section 4. Here, we define a 
function which reflects the variotis losses associated with correct and incorrec~ 
decisions, and in Section 4 we define a function which reflects the actual costs 
of administration associated with the decision rules. 
Ye define our loss function in Table 2. 
Table 2 
True State 
C c 
Decision Rule + .ell ,elO 
Outcome 
.eOl .eoo 
For example, the cost of a positive decision when C is present is .e11 . The 
first subscript of .eij denotes the decision, positive(+) or negative(-), and 
the second denotes presence or absence of the characteristic. 
When C denotes, say, the virus for AIDS, there are two points of view that 
one can take regarding this cost function; one from the perspective of society 
and the other from that of the individual. From a societal standpoint, it could 
be sensible to argue that 
.e11 s .eoo < 110 s .eo1· 
In the examples section, we consider a situation where the cost associated with 
infecting an individual by transfusion of contaminated blood is assumed to be 
.e01 - $10
6
. While there are costs associated with false positive results, they 
are expected to be much less than $106 . The individual involved would generally 
not be informed of a positive result unless it was confirmed by additional 
testing to be positive. Thus the loss .e10 would be expected to range from a 
minimum of $15, depending upon how many confirmatory tests were equivocal before 
a definite decision could be made regarding the infection status. In the event 
that individuals were informed as to the results of the screening test, these 
costs could be much higher; the ordering could vary from one individual to 
another. Drug testing is a good example of a situation where the ordering would 
vary depending upon one's perspective. In general, it would only be reasonable 
to assume .eii < .ekj for all blj. 
A generalization of our notation from section 2 regarding the conditional 
probabilities for the various outcomes of the two tests is introduced in Table 
3. 
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Table 3 
C c 
T2 i'2 T2 T2 
Tl "11 "10 Tl 911 910 
Tl "01 "oo Tl 901 900 
Thus Pr(T1 ,T2 jc) - ,,11 , Pr(T1 ,T2 jc) - 901 , etc. We define Pr(C) - ff as before, 
and the predictive values positive and negative for decision rule i as 
Pr(Cf+) - ~i and Pr(Cf-) - ~i' for i-1,2, ... ,8. For each of the eight joint 
tests in Table 1, define the sensitivity and specificity as 
'Ii - Pr((+)jC), 9i - Pr((-)jC) 
For decision rule R., the expected loss is 
1 
i=-1, ... ,8. 
(3.1) 
The values of Pr((+)fC) and Pr((-)jC) for each of the first 4 decision rules are 
presented in Table 4. 
Table 4 
Rule# Pr(+IC)(sensitivitI) Pr(-IC)(sEecificitI) 
1 
"1 - "11 + "10 91 - 900 + 901 
2 
"2 - "11 + "01 92 - 900 + 910 
3 
'13 - "11 93 - 900 + 901 910 
4 
'14 - "11 + "10 + "01 94 - 900 
Note from (3.1) that, irrespective of prevalence and losses resulting from 
either false positive or negative results, if ,,10 - ,,01 - 0, (T1T2) is optimal. 
If 901 - e10 - 0, (T1UT2) is optimal. If ,,10 - 901 - 0, T2 is optimal, and if 
,,01 = 910 - 0, T1 is optimal. Furthermore, it follows easily that the values 
for rules #5 and #6 are equivalent to those for rule #3, and similarly rules #7 
and #8 are equivalent to rule #4. 
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For a mass screening program, such as contemplated for certain diseases, it 
would be desirable to use the optimal rule. Now rule R will be preferred to R* .. 
if the expected loss under R is less than that under R*. Denote this as 
R > R*. It is straightforward to show that if k - (l10-l00)/(l10-l00+l01 -lll), 
then 
T2 > (T1vr2) ~ (T1T2) > T1 ~ Pr(CIT1i'2) < k. 
Tl> (Tlvr2) 0 (T1T2) > T2 ~ Pr(cli'1T2) < k 
(T1T2) > (Tlvr2) ~ Pr(cli'1T2UT1i'2> < k 
Pr(C,T1i'2) - Pr(C,T1T2) T2 >Tl~----------< k Pr(T1i'2) - Pr(T1T~) 
(3.2) 
Note that k - 1/2 when 210-200 ~. ,e01-l11 or more particularly if ,e00 = .e11 and 
210 = 201 . Suppose that Pr(CIT1f 2) < k < Pr(CjT1T2). Then it follows from 
(3.2) that 
T2 > (T1vr2) > T1 ; and T2 > (T1T2) > T1 , 
thus T2 would be the optimal procedure if the expense of testing were 
irrelevant. In fact, it is also the case that if T2 is optimal, then the above 
condition must hold, due to (3.2), so the condition is necessary and sufficient. 
The following necessary and sufficient conditions are shown using (3.2): 
Tl is optimal~': Pr(Cji'1T2) < k < Pr(CIT1i'2) 
T2 is optimal~ Pr(CIT1T2) < k < Pr(cli'1T2) 
(TlT2) is optimal~ Pr(CIT1i'2) < k and Pr(c(i'1T2) <k 
(T1Lfr2) is optimal~ Pr(C(T1i'2) > k and Pr(cli'1T2) > k. 
These conditions translate easily into equivalent statements regarding the 
parameters {~ij'8ij) and ff. 
(3.3) 
With the values in Table 3 fixed and known, it is possible to partition the 
I 
space of (k,ff) values into regions for which the various rules 1-4 are optimal. 
Define k* - k/(1-k), a - 901/q01 , b - 910;~10 , a* - 901/(801+~01), 
b* = 810/(910+~10). Then 
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T1 is optimal~ ff< ak*/(l+ak*), ff> bk*/(l+bk*) 
T2 is optimal~ ff< bk*/(l+bk*), ff> ak*/(l+ak*) 
(T1T2) is optimal~ ff< min{ak*/(l+ak*), bk*/(l+bk*)) 
(T1uT2) is optimal~ ff> max{ak*/(l+ak*), bk*/(l+bk*)) 
If a< b, the regions of optimality are given in Figure 1. If a> b, then the 
middle region corresponds to values of (k*,ff) for which T1 is optimal; T2 would 
thus never be optimal when a> b. 
Now assume the parameters are unknown and that prior information is 
available for ({'lij), {Dij), ff) in the form of independent Dirichlet 
distributions; namely 
aij-1 
p ( { f'/ ij )) oc: II '7 ij 
i,j 'lij ~ 0, ~ f'/ij - 1, ~ aij - a, i,j i,j 
p ( { D ij )) oc: II 
i,j 
a .. -1 
8 l.J ij 
-v-1 .;_l p(ff) oc: ff 1 (1-ff)' 
(3.5) 
Assume "training data" is available, where individuals known to have C and 
individuals known to be Care tested and a decision made as to(+) or(-) in 
each case. The likelihood corresponding to such data is 
L({f7 •• ),{D.j)) - II l.J l. • • l.,J 
r .. - n, 
l.J 
-
= n. 
Data for ff can either be direct or indirect, as in the one test case discussed 
in section 2. Direct data for ff is assumed to arise from a binomial sample; the 
corresponding likelihood is the same as in (2.1). Indirect data for a ff is 
obtained from screening data on individuals whose status with respect to C is 
unknown. This type of data is especially appropriate for small ff, since direct 
estimates of ff in such cases would often be prohibitively expensive and/or 
impossible to obtain. Gastwirth et al. (1988) and Johnson and Gastwirth (1988) 
detail Bayesian methods for estimating low prevalence from screening data based 
on a single test. We assume indirect data for ff is in the form of a screening 
test from the general population under scrutiny. Two types of screening data 
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based on joint testing are 
s1 : s1 individuals are randomly selected and tested with test #land 
s 2 individuals are randomly selected and tested with test #2 
s2 : s individuals are randomly selected and tested with both tests #1 and #2. 
The likelihoods for s1 and s2 are: 
Ll ( { ~ ij } , { 9 ij } ' w) -
2 t. s 1-t. Il {w~i + (1-w)(l-Oi)} 1 {w(l-~1) + (1-w)Oi} 
1 
i-1 
Screening data could also be obtained from the other sampling schemes. 
For the above sampling designs, the total likelihoods are L(w)L({~ij},{Oij}) 
and Li({qij},{91 .),w)L({~ .. },{9 •. }), i-1,2. With direct information for w, the J 1J 1J 
·posteriors for {~ij},{Oij} and ware independent and Dirichlet. Writing "d" for 
data, 
(3.6) 
wld - Beta(7 + t, 7 + v-t ). C C 
Posterior means and variances and the sensitivities and specificities of all 
decision rules are easily obtained under this setup. For example, the 
sensitivity for the test T1 is estimated as 
E(~lld) - (rll + rlO +all+ alO)/(n + a); 
the prevalence estimate is 
E(wld) - (7 + t )/7 + v). 
C 
Joint posteriors under screening data s1 and s2 are easily obtained, but are 
computationally burdensome. Simplifications in the high accuracy and low 
prevalence case (Johnson and Gastwirth, 1988) are possible, but will be reported 
elsewhere. For the remainder of this paper, we assume that direct information 
is available for w, and thus the posterior distribution of all parameters is 
given by (3.6). In those cases where current data are unavailable, one's prior 
knowledge of win conjunction with data for the ~.j's and 9i.'s may be 
i 1 J 
sufficiently precise to warrant an analysis without current data for w. 
The predictive probability of C for an individual that has just tested 
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positive according to decision rule i is calculated as Pr(Cl(+),d) = 
E(w.l(+),d). Upon application of Bayes theorem, this can also be expressed as _ 
i 
in (2.2) with (~i,9i) substituted for (~,9). Similarly, Pr(Cl(-),d) = 
E(~.1(-),d). Under our sampling scheme for w, all expectations of products 
i 
result in products of expectations due to independence. For example, 
E(wjd)E(~ild) 
Pr(Cj(+),d) - E(w!d)E(~.!d) + E(l-w!d)E(l-9.ld) . 
1 1 
From (3.1) the expected loss, given rule i, is 
E(LIRi,d) - E(w~ild)(l11-lo1> + E((l-w)9ijd)(loo·l10> (3.7) 
+ E(wjd)lOl + E(l-wjd)l10 . 
Upon substitution of particular values for the sensitivity and specificity for 
different rules, it follows from (3.7) that (3.2) and (3.3) must hold with all 
conditional probabilities replaced with corresponding predictive probabilities. 
For example, replace Pr(CjT1T2) with Pr(CIT1T2 ,d) = 
E(w~10 1d)/E(w~10 + (1-w)910 1d). Furthermore replace Pr(C,T1T2), Pr(T1T2) etc. 
with their posterior expectations. 
4. Costs of Administration 
In any large scale screening program costs of administering the tests will 
be of considerable concern. For example, with regard to AIDS, the ELISA test is 
an order of magnitude less expensive than the Western Blot. Also, there may be 
a differential in the cost of a simultaneous administration of both tests in 
contrast to their sequential administration. Among other things this may result 
from having to store the sample until the result from the first test is 
obtained, or from asking a testee to return for testing. 
Once all of the actual testing costs are carefully ascertained, their 
incorporation into a complete decision analysis can be made without much 
difficulty. The major problems are in assessing, in some reasonable way, the 
original losses on a comparable monetary scale with the actual expense of 
testing. Another decision analytic consideration would be for a situation where 
a program was limited to a fixed amount of funding because of competing 
concerns. In this case, procedures that optimize certain well-defined benefits 
would be of critical interest. 
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Let Ki be the cost of administering test i alone, and let Kij be the cost of 
administering test i followed by administering test j. Let K(l2) be the cost of 
administering both tests simultaneously. Clearly, it is reasonable to assume 
that Kij ~ K(l2) ~ max(K1 ,K2). Ip testing for a disease, for example, there may 
be storage and retrieval costs for sequential sampling. The expected costs for 
the eight decision rules are given in Table 5. 
Table 5 
Decision Rule E(Cost) 
1 Kl 
2 K2 
3 K(12) 
4 K(l2) 
5 ~ + (K12-K1)Pr(T1) 
6 K2 + (K21 -K2)Pr(T2) 
7 
~+ (K12 -K1)Pr(T1) 
8 K2 + (K21 -K2)Pr(T2) 
The above probabilities are conditional on the parameters. If they were 
unknown, then they would be conditional on d. 
Define the total expected loss for decision rule i to be the sum of the 
appropriate expected loss from (3.1) or (3.7) and the appropriate expected cost 
from Table 5. The total expected loss for rule 5 is greater than that for rule 
3 if and only if E(Cost) for rule 5 is greater than that for rule 3. The same 
holds true for rule 6 compared with rule 3. Rule 7 is preferable to rule 4 if 
E(Cost) for rule 7 is less than E(Cost) for rule 4, and the same holds true for 
rule 8 compared with rule 4. The decision as to whether to consider sequential 
tests versus simultaneous tests is based purely on costs. Thus if K12 = K21 = 
K(l2) or more particularly if Kij = K(l2) - K1+K2 , then rules 5 and 6 will be 
preferable to rule 3 and rules 7 and 8 will be preferable to rule 4. 
5. Illustrations 
In this section we consider three data sets; two concerning AIDS and one 
concerning feline leukemia virus (FLV). 
The first two data sets are abstracted from studies that were designed to 
compare different tests for detecting antibodies to the AIDS virus (Burkhardt et 
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al., (1987); Sandstrom et al., (1985)). Neither study contained information for 
ff. In both of these studies, we utilize data for the accuracies in conjunction~ 
with independent information for ff from the population of blood donors in Canada 
(Nusbacher et al., (1986)). 
For both of the AIDS studies, individual serum specimens were tested with two 
commercial preparations. For our purposes, weak positives and negatives were 
considered positive. In both studies, specimens that were weakly positive or 
negative on either test, or that resulted in discrepant results(((+)(-)) or 
((-),(+)) were retested in a variety of ways, including the Western Blot test, 
until an ultimate determination as to the true status of the specimen was 
ascertained. In one of the studies, a subsample of((+)(+)} and((-)(-)} 
samples were given confirmatory tests and one discrepancy was noted. From these 
studies, we have abstracted 2x2x2 tables of counts in the form of Table 3. It 
will be assumed that these are the same tables that would have arisen if all 
specimens were given confirmatory tests. Since there are possible errors in our 
abstraction of the data, the analyses are only illustrative. 
The third data set is assumed to have been obtained from blood samples taken 
from a random sample of cats (Jarrett et al., 1982). Three tests were performed 
on each specimen; one of the tests is assumed to be superior to the other two 
and will be considered to be a "gold standard". Thus, these data are assumed to 
contain information for ff as well as for the accuracies. 
Assuming a generic measurement scale for the moment, let 100 - 111 - 0 and 
101 - 1 ~ 110 - q > 0 for all those studies. This reflects a societal attitude 
that it is worse to infuse contaminated blood than it is to falsely identify a 
healthy donor in the AIDS examples; and that it is worse to misinform an 
individual cat owner that his/her cat is FLV free when it is infected than it is 
to misdiagnose the cat as having FLV when it doesn't. With these assumptions, 
k = q/(l+q) and k* - q. 
For the priors, we assume a11 - 3.9 - a00 , a10 - a01 - .5 - a10 - a 01 , and 
aoo - .1 - all for all examples. Thus, our prior for (~ij) has a weight, 
a11+a10+a01+a00 - 5, which is equivalent to a sample of size n - 5 for the data. 
The same statement holds for (9ij). Furthermore, our prior reflects the belief 
that simultaneous correct screening results are quite likely (prior probability 
= 3.9/5 - .78) and that incorrect results are considerably less likely, but 
still plausible. 
Information for ff is the same for both AIDS studies. We utilize Canadian 
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data obtained by Nusbacher et al. (1986) and analyzed by Gastwirth, Johnson and 
Reneau (1988). The Canadians administered a questionnaire which was designed to 
encourage "high risk" individuals to donate their blood anonymously for research 
purposes rather than for possible transfusion. Among 94,946 individuals whose 
blood was not utilized for research purposes, 405 samples tested positive on an 
Abbott ELISA screening test, and among those, 14 were confirmed positive by 
Western Blot. If we assume the remaining 94,091 negative samples were actually 
uncontaminated, then these data could be treated as a Bin (94496,ff) sample. The 
prevalence ff is the proportional contaminated samples in the Canadian blood that 
is available for transfusion. With an improper B(l,O) prior for~, E(ffld) = 
.000148. Alternatively, one could simply assume a beta prior with mean .000148 
and an appropriate standard dev~,ation. For the FLV data, we assume a B(l,O) 
prior for ff since data is available for ff in the experiment. 
Example 1: Burkhardt, Mertens, and Eggers (1987) sampled 503 individuals and 
tested each serum specimen with an Abbott ELISA test and a DuPont ELISA test. 
The following data on accuracies were abstracted from their study. 
C 
DuPont + 
Abbott 
+ 
fFro7 
IIII1 
Table 6 
c 
i DuPont 
I 
+ 
Abbott 
+ 
~ ~ 
We do not use information for ff or q as yet. Utilizing the data displayed 
in Table 6, we obtain independent Dirichlet posteriors for ({q .. }{8.j},~). 
1J 1 
The conditional predictive probabilities of positive and negative results 
for rules 1-4 are listed in Table 7. 
Rule 
DuPont 
Abbott 
Table 7 
Pr<+IC,d} (sensitivity} 
.984 
.994 
(DuPontnA.bbott) 
(DuPontUAbbott) 
.979 
.999 
Pr<-IC,d) (specificity} 
.958 
.924 
.981 
.901 
These probabilities are calculated as Pr(+IC,d) - E(qld), Pr(-IC,d) - E(Bld). 
In order to determine the optimality regions for rules 1-4, we obtain 
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a - E(901 fd)/E(~01 fd) - 3.70 and b - E(910 1d)/E(~lOfd) - 4.50. Optimality is 
determined according to (3.4) and is viewed pictorially by consideration of 
Figure 1 with a* - .79, b* - .82, k* - q, and with E(~fd) substituted for w. 
The DuPont ELISA alone would not be optimal for any q and regardless of the 
value of E(wld). 
If the posterior for ff has mean .000148, as discussed above for the Canadian 
transfusion pool, it remains to consider q before making a decision regarding 
the choice among rules 1-4, without regard to costs of administering the tests. 
Suppose that the value $106 is attached to the life of an individual that is 
transfused with contaminated blood. In this instance, the rule (DuPont n 
Abbott) is preferable if q > $40, the rule (DuPont u Abbott) is preferable if 
q < $33, and the rule (Abbott) is preferable if $33 < q < $40. 
We now consider the expenses associated with the administration of these 
tests. For simplicity, assume K1 - K2 - K, K(l2) - ~ 2 = K21 - 2K. Then 
equating T1 = Dupont and T2 = Abbott we obtain 
where 
E(CostfR1) = E(CostlR2) = K, E(CostlR3) = E(CostlR4) = 2K 
E(CostlR5) = K(l + Pr(T1 1d)}, E(CostlR6) = K(l + Pr(T2 1d)}, 
E(CostlR7) - K(l + Pr(T1 1d)}, E(CostlR8) = K{l + Pr(T2 1d)}, 
Pr(T1 1d) - .941 E(ffld) + .042, Pr(T2 1d) = .918 E(wld) + .076. 
Thus for the situation above with E(wld) - .000148, 
E(CostlR5) ~ 1.042K, E(CostlR6) ~ 1.076K 
E(CostlR7) ~ 1.958K, E(CostlR8) ~ 1.924K. 
Suppose K - $1 and q - $25. Without regard to the cost of administering a 
test, T1UT2 is optimal. The total expected losses, per individual, for the 
eight rules are $4.42, $3.79, $5.58, $4.62, $4.46, $3.87, $5.54, and $4.54, 
respectively. Thus T2 would be optimal overall. If on the other hand K = $5 
and q - $50, then (T1nT2) is optimal without considering test expense. The 
total expected costs for the eight rules are $11.57, $13.49, $15.01, $20.05, 
$10.22, $10.39, $19.84, and $19.67 respectively. Thus the sequential rule r1t 2 
would be optimal. The values of PVP and 1-PVN for the rules are given in Table 
8. 
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Rule 
Tl 
T2 
(T1nT2) 
(TlUT2) 
Pr<cl<+).d) - PVP 
.0035 
.0019 
.0076 
.0015 
Table 8 
Pr<Cl<-),d) - 1-PVN 
-6 2.4 X 10 
.8 X 10-6 
3.1 X 10-6 
.2 X 10-6 
Example 2: These data are abstracted from Sandstrom et al. (1985). A total of 
225 sera were tested by indirect immunofluorescence assay (IFA) and with an 
ELISA test. The data is given in Table 9. 
C 
IFA + 
+ 
139 
1 
ELISA 
4 
0 
Table 9 
c 
IFA + 
+ 
7 
23 
ELISA 
0 
51 
Since a - 27.1, b - .19, a* - .96 and b* - .16, the ELISA is never optimal, and 
the IFA is optimal for far more values of (q,E(ff(d)) than in the previous 
example. With E(wld) - .000148, and with a $106 cost of a false negative 
where T1 - IFA and T2 - ELISA, T1nT2 is optimal for q ~ $778.95, T1 is optimal 
for $5.46 < q < $778.95 and T1UT2 is optimal for q s $5.46. Expenses of tests 
are not considered here. The PVP and 1-PVN for the rules are listed in Table 
10. 
Rule 
Tl 
T2 
T1nT2 
T1UT2 
PVP 
.0017 
.0004 
.0017 
.0004 
Table 10 
1-PVN 
1. 1x10·6 
7.lx10· 6 
6.6x10· 6 
.2x10· 6 
Example 3: These data were taken directly from Jarrett et al. (1982). In this 
study, 412 blood samples were taken from cats. Three tests for feline leukemia 
virus (FLV) were applied to each sample, namely the ELISA test, 
immunofluorescence (IFA) and virus isolation (VI). We assume VI is a "gold 
standard" for the purposes of our discussion, which it would evidently be under 
16 
ideal circumstances (Jarrett et al. 1982). The results were obtained from Table 
3 of Jarrett et al. (1982) and are displayed in Table 11. 
C 
IFA + 
ELISA 
+ 
Table 11 
c 
IFA + 
ELISA 
+ 
l3fl7 
m=Tifil 
Since a - 1.20, b - .44, a* - .55 and b* - .31, the ELISA alone is never 
optimal. Refer to Figure 1 to visualize the regions of optimality for the other 
tests. If the data from Table 11 were obtained as a random sample of size 412 
from some meaningful population, like the population of all household cats, for 
example, we would obtain the likelihood contribution for ff 
L(w) « w49(1-w)363_ 
Assuming a B(l,O) prior for w, we obtain a B(50, 363) posterior and consequently 
E(ffld) .12. Assuming a loss of $100 for a false negative result, (IFA u 
Elisa) is optimal if the cost of a false positive result q < $11.36, IFA is 
optimal if $11.36 < q < $31.00, and (IFA n ELISA) is optimal if q > $31.00. The 
PVP and 1-PVN values for the rules are given in Table 12, where T1 - ELISA and 
T2 - ELISA. 
Table 12 
Rule PVP 1-PVN 
Tl .92 .007 
T2 .65 .002 
T1nT2 .94 .008 
T1UT2 .67 .0003 
6. Remarks 
We have attempted to present the ingredients that are required in designing 
a mass screening program, as well as how to conduct one in an optimal manner. 
Although we have restricted our concern to at most two binary tests, it is 
conceptually clear how one would proceed formulaically with several such binary 
tests. There also should be no great difficulty in managing such a program when 
several dichotomous covariates are also taken into account. Greater complexity 
arises when including several continuous covariates into such a decision 
17 
theoretic framework. 
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